Aadi Bioscience, Inc. (“Aadi”) (NASDAQ:AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it will present a poster at the Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held this year from October 7th -10th.
The Company will present preclinical data evaluating nab-sirolimus (ABI-009) in PTEN-deleted and TSC2-deleted cancer models in comparison with other mTOR inhibitors sirolimus and everolimus and evaluating their effects on important downstream targets S6 and 4EBP1.
Learn more about Aadi’s development of therapies that target the genetic drivers of cancers of the mTOR pathway at www.aadibio.com.
Aadi’s presentation at the 2021 AACR-NCI-EORTC International Conference:
All times noted are U.S. Eastern Time (ET).
Presentation Title: nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts
Author: Shihe Hou, Ph.D., Aadi Bioscience, Inc.
Session: mTOR/PI3-kinase, P138
Session Date/Time: Thursday, October 7, 9:00 a.m. and on-demand throughout conference
The poster will be posted to the Events and Presentations section of Aadi Bioscience’s website after 9 am ET on October 7th.
